On the evening of November 28, Beijing time, the official news of the International Tennis Integrity Agency said that Swiatek, who is currently ranked No. 2 in the women's singles world, tested positive for doping and was banned for 1 month, and the player was temporarily banned from September 12 to October 4, and she also missed the China Open and Wuhan Open in the Asian season. And this will count towards the penalty, so Swiatek has eight days left in his ban.
It is reported that the reason why Swiatek was banned for one month was because one of her samples was tested for the banned drug trimetazidine after she stopped in the top 4 in Cincinnati on August 12 this year. Swiatek admits that she was mistakenly convinced, as she underwent a rigorous ITIA (International Tennis Integrity Agency) inspection process, which was "incredibly low".
And during that time, Swiatek did not perform well. She defended her French Open title by upsetting her third round at Wimbledon, the last eight at the US Open, and at the Olympics, Swiatek suffered a 2-0 semi-final defeat to eventual gold medallist Zheng Qinwen of China on clay, her best match. Notably, this is also the only time in Zheng's career that he has defeated Swiatek.
And the banned drug trimetazidine used by Swatai to overcome is believed to be familiar to Chinese netizens. In January 2014, trimetazidine was added to the World Anti-Doping Agency's banned list. The legendary Chinese swimming player Sun Yang was banned for 3 months for taking trimetazidine for viral myocarditis in May of that year. In 2021, 23 members of the Chinese swimming team were recruited, and they were all trimetazidine positive.
Trimetazidine, which was marketed in China in 2000, shows that the drug is used for the symptomatic treatment of stable angina pectoris that is poorly controlled or intolerant by first-line antianginal therapy. Clinically, it is often used for the preventive treatment of angina attacks.